secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001104659-25-067444
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma appoints Philip Lemons and Richard Baek to Board of Directors
------------------------------------------------------------------------------

- Board expanded from 5 to 6 members with appointment of Lemons and Baek effective July 10, 2025.
- Philip Lemons, 54, brings clinical R&D expertise; serves as Chief Business Officer at ICE Global Consulting.
- Richard Baek, 33, brings financial oversight and regulatory compliance; VP Finance at Studio City PXL.
- No arrangements or transactions with the company requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925067444/0001104659-25-067444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925067444/tm2520692d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-067444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer